NCT02681510View on ClinicalTrials.gov

UW-CTRI Triple Medication Smoking Cessation Study

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 13, 2016

Study Completion Date

June 13, 2016

Conditions
Smoking
Interventions
DRUG

Varenicline

Standard FDA approved 12 weeks of treatment with Varenicline

DRUG

Nicotine Transdermal Patch

Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch

DRUG

Nicotine Mini

Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge

Trial Locations (1)

53711

UW CTRI, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT02681510 - UW-CTRI Triple Medication Smoking Cessation Study | Biotech Hunter | Biotech Hunter